ASH 2017 | Venetoclax resistance and alternative treatments in CLL

John Gribben

Although little is currently known about the mechanisms of resistance to venetoclax, researchers are constantly looking for new drugs that can be used in case of resistance or intolerance to drugs such as venetoclax, ibrutinib or obinutuzumab. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of the Barts Cancer Institute, London, UK, spoke to us about venetoclax resistance, and described some exciting drugs currently in development for the treatment of chronic lymphocytic leukemia (CLL).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter